Previous close | 5.65 |
Open | 5.70 |
Bid | 5.55 x N/A |
Ask | 5.80 x N/A |
Day's range | 5.60 - 5.85 |
52-week range | 3.70 - 6.60 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 12 Aug 2024 - 16 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Last week, Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) insiders, who had purchased shares in the previous 12 months were...
The FDA will meet with its Genetic Metabolic Diseases Advisory Committee to review Zevra's (ZVRA) new drug application for pipeline candidate arimoclomol. Shares of Zevra gains on the news.
Zevra Therapeutics (ZVRA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.